Loading...
•
Sep 30, 2023
Liquidia Q3 2023 Earnings Report
Liquidia reported financial results for the third quarter of 2023 and provided a corporate update.
Key Takeaways
Liquidia Corporation reported revenue of $3.7 million and a net loss of $15.8 million for the third quarter ended September 30, 2023. The company is focused on advancing YUTREPIA and L606, with key regulatory and legal events anticipated.
Received PDUFA goal date of January 24, 2024, to add PH-ILD indication to YUTREPIA label.
Oral arguments for appeal of PTAB ruling of ‘793 Patent invalidity scheduled for December 4, 2023.
Fully transitioned clinical development of L606 from Pharmosa to Liquidia for the North American territory.
Cash totaled $76.2 million as of September 30, 2023.
Revenue by Segment
Forward Guidance
Liquidia is looking forward to upcoming key events that will help unlock the value of YUTREPIA, with pivotal legal arguments set in early December and potential label expansion of YUTREPIA for PH-ILD in late January. In anticipation of potential successful resolution of the ongoing legal dispute with United Therapeutics and receiving final FDA approval, they have expanded their top-tier sales force.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...